PE20230493A1 - Vacuna contra hpv - Google Patents
Vacuna contra hpvInfo
- Publication number
- PE20230493A1 PE20230493A1 PE2022001736A PE2022001736A PE20230493A1 PE 20230493 A1 PE20230493 A1 PE 20230493A1 PE 2022001736 A PE2022001736 A PE 2022001736A PE 2022001736 A PE2022001736 A PE 2022001736A PE 20230493 A1 PE20230493 A1 PE 20230493A1
- Authority
- PE
- Peru
- Prior art keywords
- hpv
- hpv vaccine
- virus
- vaccine
- vlps
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente divulgacion proporciona, entre otras cosas, una composicion farmaceutica que incluye un adyuvante de nanoparticulas lipidicas y una vacuna contra el virus del papiloma humano (HPV) que comprende particulas similares a virus (VLP) de HPV de al menos un tipo de virus del papiloma humano (HPV) seleccionado del grupo que consiste en los tipos de HPV: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73 y 82
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062976673P | 2020-02-14 | 2020-02-14 | |
PCT/US2021/017157 WO2021163002A1 (en) | 2020-02-14 | 2021-02-09 | Hpv vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20230493A1 true PE20230493A1 (es) | 2023-03-23 |
Family
ID=74853762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022001736A PE20230493A1 (es) | 2020-02-14 | 2021-02-09 | Vacuna contra hpv |
Country Status (20)
Country | Link |
---|---|
US (3) | US11638754B2 (es) |
EP (1) | EP4103227A1 (es) |
JP (1) | JP2023516904A (es) |
KR (1) | KR20220140901A (es) |
CN (1) | CN115103687A (es) |
AR (1) | AR121292A1 (es) |
AU (1) | AU2021219652A1 (es) |
BR (1) | BR112022015313A2 (es) |
CA (1) | CA3166256A1 (es) |
CL (1) | CL2022002167A1 (es) |
CO (1) | CO2022011392A2 (es) |
CR (1) | CR20220395A (es) |
DO (1) | DOP2022000168A (es) |
EC (1) | ECSP22063122A (es) |
IL (1) | IL295234A (es) |
JO (1) | JOP20220187A1 (es) |
MX (1) | MX2022009964A (es) |
PE (1) | PE20230493A1 (es) |
TW (1) | TW202140069A (es) |
WO (1) | WO2021163002A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023023152A1 (en) * | 2021-08-19 | 2023-02-23 | Merck Sharp & Dohme Llc | Thermostable lipid nanoparticle and methods of use thereof |
CN115850686A (zh) * | 2021-09-27 | 2023-03-28 | 广州谷森制药有限公司 | 新型氘代peg脂质化合物、其制备方法、组合物和应用 |
US11951177B2 (en) * | 2022-03-23 | 2024-04-09 | Nanovation Therapeutics Inc. | High sterol-containing lipid nanoparticles |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
CA2202090C (en) | 1994-10-07 | 2012-04-17 | Lutz Gissmann | Papilloma virus-like particles, fusion proteins as well as processes for their production |
US5820870A (en) | 1995-03-22 | 1998-10-13 | Merck & Co., Inc. | Recombinant human papillomavirus type 18 vaccine |
EP0910343A1 (en) | 1996-07-03 | 1999-04-28 | University Of Pittsburgh | Emulsion formulations for hydrophilic active agents |
WO2002087541A1 (en) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
US7514099B2 (en) | 2005-02-14 | 2009-04-07 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
PT2311848E (pt) | 2002-12-23 | 2013-10-03 | Vical Inc | Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano |
CN100506999C (zh) | 2003-03-24 | 2009-07-01 | 麦克公司 | Hpv31l1在酵母中的优化表达 |
MY140664A (en) | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
MY139500A (en) | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
CA2560487C (en) | 2004-03-24 | 2013-01-29 | Merck & Co., Inc. | Optimized expression of hpv 52 l1 in yeast |
AU2005248361B2 (en) | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
CA2606092A1 (en) | 2005-04-26 | 2006-11-02 | Glaxosmithkline Biologicals S.A. | Vaccine |
TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
EP2129394B1 (en) * | 2007-03-09 | 2012-06-20 | Merck Sharp & Dohme Corp. | Papillomavirus vaccine compositions |
US20100055168A1 (en) | 2008-04-16 | 2010-03-04 | Abbott Laboratories | Cationic lipids and uses thereof |
US20090285881A1 (en) | 2008-04-16 | 2009-11-19 | Abbott Laboratories | Cationic lipids and uses thereof |
US20100104629A1 (en) | 2008-04-16 | 2010-04-29 | Abbott Laboratories | Cationic lipids and uses thereof |
US20090263407A1 (en) | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic Lipids and Uses Thereof |
US20100076055A1 (en) | 2008-04-16 | 2010-03-25 | Abbott Laboratories | Cationic Lipids and Uses Thereof |
US20100055169A1 (en) | 2008-04-16 | 2010-03-04 | Abbott Laboratories | Cationic lipids and uses thereof |
WO2009132131A1 (en) | 2008-04-22 | 2009-10-29 | Alnylam Pharmaceuticals, Inc. | Amino lipid based improved lipid formulation |
EP2326331A4 (en) | 2008-08-18 | 2013-05-15 | Merck Sharp & Dohme | NOVEL LIPID NANOPARTICLES AND NEW COMPONENTS FOR NUCLEIC ACID ADMINISTRATION |
WO2010030739A1 (en) | 2008-09-10 | 2010-03-18 | Abbott Laboratories | Polyethylene glycol lipid conjugates and uses thereof |
US20100099738A1 (en) | 2008-09-10 | 2010-04-22 | Abbott Laboratories | Polyethylene glycol lipid conjugates and uses thereof |
CN104119242B (zh) | 2008-10-09 | 2017-07-07 | 泰米拉制药公司 | 改善的氨基脂质和递送核酸的方法 |
WO2010105209A1 (en) | 2009-03-12 | 2010-09-16 | Alnylam Pharmaceuticals, Inc. | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
US8952955B2 (en) | 2009-06-17 | 2015-02-10 | Sharp Kabushiki Kaisha | Display driving circuit, display device and display driving method |
US9181295B2 (en) | 2009-08-20 | 2015-11-10 | Sirna Therapeutics, Inc. | Cationic lipids with various head groups for oligonucleotide delivery |
CN102905763B (zh) | 2009-12-23 | 2015-06-17 | 诺华股份有限公司 | 脂质、脂质组合物和使用它们的方法 |
ES2384060B1 (es) | 2010-03-24 | 2013-09-23 | Lipotec S.A. | Cápsulas de nanopartículas lipídicas. |
KR101878361B1 (ko) | 2010-09-20 | 2018-08-20 | 시르나 쎄러퓨틱스 인코퍼레이티드 | 올리고뉴클레오티드 전달을 위한 신규 저분자량 양이온성 지질 |
JP6050811B2 (ja) | 2011-06-24 | 2016-12-21 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | アルミニウムアジュバントを含むhpvワクチン製剤およびその産生方法 |
EP3110401A4 (en) * | 2014-02-25 | 2017-10-25 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
EP3364982A4 (en) * | 2015-10-22 | 2019-04-17 | ModernaTX, Inc. | VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES |
-
2021
- 2021-02-09 JP JP2022548590A patent/JP2023516904A/ja active Pending
- 2021-02-09 EP EP21709566.0A patent/EP4103227A1/en active Pending
- 2021-02-09 US US17/170,948 patent/US11638754B2/en active Active
- 2021-02-09 JO JOP/2022/0187A patent/JOP20220187A1/ar unknown
- 2021-02-09 WO PCT/US2021/017157 patent/WO2021163002A1/en active Application Filing
- 2021-02-09 PE PE2022001736A patent/PE20230493A1/es unknown
- 2021-02-09 BR BR112022015313A patent/BR112022015313A2/pt unknown
- 2021-02-09 US US17/799,464 patent/US20230123584A1/en active Pending
- 2021-02-09 TW TW110104887A patent/TW202140069A/zh unknown
- 2021-02-09 AU AU2021219652A patent/AU2021219652A1/en active Pending
- 2021-02-09 CN CN202180014380.2A patent/CN115103687A/zh active Pending
- 2021-02-09 CA CA3166256A patent/CA3166256A1/en active Pending
- 2021-02-09 MX MX2022009964A patent/MX2022009964A/es unknown
- 2021-02-09 KR KR1020227031070A patent/KR20220140901A/ko unknown
- 2021-02-09 IL IL295234A patent/IL295234A/en unknown
- 2021-02-09 AR ARP210100329A patent/AR121292A1/es unknown
- 2021-02-09 CR CR20220395A patent/CR20220395A/es unknown
-
2022
- 2022-08-10 CL CL2022002167A patent/CL2022002167A1/es unknown
- 2022-08-11 EC ECSENADI202263122A patent/ECSP22063122A/es unknown
- 2022-08-12 CO CONC2022/0011392A patent/CO2022011392A2/es unknown
- 2022-08-12 DO DO2022000168A patent/DOP2022000168A/es unknown
-
2023
- 2023-03-10 US US18/181,754 patent/US20230270850A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
DOP2022000168A (es) | 2022-09-30 |
US11638754B2 (en) | 2023-05-02 |
JOP20220187A1 (ar) | 2023-01-30 |
CO2022011392A2 (es) | 2022-08-19 |
WO2021163002A1 (en) | 2021-08-19 |
US20230123584A1 (en) | 2023-04-20 |
US20230270850A1 (en) | 2023-08-31 |
KR20220140901A (ko) | 2022-10-18 |
CR20220395A (es) | 2022-10-27 |
TW202140069A (zh) | 2021-11-01 |
AU2021219652A1 (en) | 2022-08-18 |
JP2023516904A (ja) | 2023-04-21 |
BR112022015313A2 (pt) | 2022-09-27 |
CA3166256A1 (en) | 2021-08-19 |
AR121292A1 (es) | 2022-05-04 |
CN115103687A (zh) | 2022-09-23 |
EP4103227A1 (en) | 2022-12-21 |
IL295234A (en) | 2022-10-01 |
CL2022002167A1 (es) | 2023-02-03 |
US20210252138A1 (en) | 2021-08-19 |
ECSP22063122A (es) | 2022-11-30 |
MX2022009964A (es) | 2022-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20230493A1 (es) | Vacuna contra hpv | |
Cimica et al. | Adjuvant formulations for virus-like particle (VLP) based vaccines | |
JP2016185988A5 (es) | ||
PE20061287A1 (es) | COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y EL ADYUVANTE TH-1 | |
AR077396A2 (es) | EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS | |
DOP2017000294A (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
AR041880A1 (es) | Composicion inmunogena | |
AR106026A1 (es) | Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos | |
CO6480995A2 (es) | Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv | |
JP2011225578A5 (es) | ||
PE20151588A1 (es) | Vacuna contra el virus del dengue | |
BR112018011331A2 (pt) | mutante de proteìna l1 de papillomavirus humano tipo 11 | |
AR103427A1 (es) | Vacuna contra la fiebre aftosa | |
CA2510457A1 (en) | Hpv-16 and -18 l1 vlp vaccine | |
PE20110327A1 (es) | Vacuna contra el virus de papiloma humano | |
AR054259A1 (es) | Vacuna contra virus de papiloma humano (hpv) | |
CY1113830T1 (el) | Εμβολιο εναντι hpv16 και hpv18 και τουλαχιστον ενος αλλου τυπου hpv ο οποιος επιλεγεται απο hpv 31,45 ή 52 | |
PE20230349A1 (es) | Vacunas para la papilomatosis respiratoria recurrente y metodos para usar estas | |
SG153837A1 (en) | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 | |
MX2023012530A (es) | Composición y metodos de vacuna adyuvada. | |
CL2013002723A1 (es) | Metodo de produccion de una particula semejante a virus (vlp) de alfavirus salmonido (sav) en celulas de insecto. | |
MX2022000777A (es) | Composicion de inmunogenicidad polivalente para el virus de papiloma humano. | |
AR041515A1 (es) | Vacuna a dna contra el virus de papiloma humano | |
MX2022004869A (es) | Vacuna de particulas similares al virus chikungunya y metodos de uso de la misma. | |
AR074485A1 (es) | Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos |